Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.36 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833368 | 1.00 | POLB (0.46) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL12525584 | 1.00 | POLB (0.46) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL12522790 | 0.91 | POLB (0.43) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL16918608 | 0.91 | POLB (0.43) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL18672182 | 0.88 | POLB (0.47) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL9909460 | 0.87 | POLB (0.44) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL25579717 | 0.86 | POLB (0.49) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL23348448 | 0.85 | POLB (0.47) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL6422530 | 0.85 | POLB (0.47) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL14853784 | 0.85 | POLB (0.47) | POLBMEN1USP2KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | POLB 169/4885MEN1 4103/4885USP2 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.